http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103788085-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2012-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2016-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2016-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-103788085-B |
titleOfInvention | 2-(quinazoline-4-amino)-5-thiazole carboxamides analog derivative and bio-pharmaceutical purposes thereof |
abstract | The invention belongs to field of biological pharmacy, relate to 2 (quinazoline 4 amino) 5 thiazole carboxamides analog derivatives and bio-pharmaceutical purposes thereof, the present invention defines Src active pocket based on the complex crystal structure of high-quality Src receptor tyrosine kinase and its inhibitor saracatinib, and search known chemicals storehouse by virtual screening software DOCK at high speed and accurate scoring functions, it is thus achieved that Src is had 2 (quinazoline 4 amino) 5 thiazole carboxamides micromolecular compound of higher inhibitory activity.Through biological activity test, result confirms, described compound has relatively high inhibition effect to Src receptor tyrosine kinase, the tumour medicine that antineoplastic especially causes can be prepared because Src signal transduction of kinases system fading margin is disorderly, and as lead compound synthesizing new Src inhibitors of kinases, it is especially useful in treat the tumor disease relevant to Src. |
priorityDate | 2012-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.